'STIC-like' lesions in ovarian low-grade serous carcinoma: a diagnostic pitfall

Affiliations

Comment

Jesús Machuca-Aguado et al. Histopathology. 2023 Sep.

. 2023 Sep;83(3):489-492.

doi: 10.1111/his.14967. Epub 2023 Jun 25.

No abstract available

Comment on

Revising the WHO classification: female genital tract tumours.
Cree IA, White VA, Indave BI, Lokuhetty D. Cree IA, et al. Histopathology. 2020 Jan;76(1):151-156. doi: 10.1111/his.13977. Histopathology. 2020. PMID: 31846528 Review.

1. Köbel M, Kalloger SE, Huntsman DG et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int. J. Gynecol. Pathol. 2010; 29; 203-211.
1. Singh N, Gilks CB, Wilkinson N, McCluggage WG. The secondary Mullerian system, field effect, BRCA, and tubal fimbria: our evolving understanding of the origin of tubo-ovarian high-grade serous carcinoma and why assignment of primary site matters. Pathology 2015; 47; 423-431.
1. Singh N, Gilks CB, Wilkinson N, McCluggage WG. Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal. Histopathology 2014; 65; 149-154.
1. Singh N, Gilks CB, Hirshowitz L, Wilkinson N, McCluggage WG. Adopting a uniform approach to site assignment in tubo-ovarian high-grade serous carcinoma: the time has come. Int. J. Gynecol. Pathol. 2016; 35; 230-237.
1. Singh N, Gilks CB, Hirschowitz L et al. Primary site assignment in tubo-ovarian high-grade serous carcinoma: consensus statement on unifying practice worldwide. Gynecol. Oncol. 2016; 141; 195-198.